Suven starts clinical trials of SUVN-502 in Europe

Hyderabad, Jun 18 (UNI) Suven Life Sciences Ltd, a drug discovery and development company today announced that it has commenced Phase I clinical trials of SUVN-502, intended for the symptomatic treatment of Alzheimer's disease.

According to a press release issued here today, SUVN-502, a potent, safe, highly selective, brain penetrant and orally active antagonist at a nonperipheral, CNS receptor site 5-HT6, is intended for the symptomatic treatment of Alzheimer's disease and other disorders of memory and cognition like Attention deficient hyperactivity, Parkinson and Schizophrenia.

The study, being conducted at Basel, Switzerland, under a Clinical Trial Application (CTA), approved by SwissMedic, the regulatory authority of Switzerland, is expected to be completed by December this year.

The Phase I study is being conducted by using single and multiple oral doses with the objective of assessing safety and bioavailability of SUVN-502 in 67 healthy human beings.

Company CEO Venkat Jasti said, ''SUVN-502 is an exciting molecule and the first NCE of Suven to enter the clinic from a pipeline of six NCEs.

Company Vice President (Discovery Research) Ramakrishna Nirogi said, ''Pre-clinical studies have demonstrated SUVN-502 to be highly potent, safe and orally available with good bioavailability across species tested. The molecule also exhibited excellent selectivity over other targets.'' We believe that SUVN-502 has great potential to become a novel treatment for disorders affecting memory and cognition in Alzheimer's and other dementia he added.

UNI VA ROY SS AK ND1644